ReviewEvidence-based complementary and alternative medicine : eCAM2021
Processing and Compatibility of
Review in Evidence-based complementary and alternative medicine : eCAM, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 31 citations in OpenAlex.
- Dehydrocorydaline Exerts Anti-Pancreatic Cancer Effects Through the PI3K/Akt/mTOR Pathway.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Plant-Derived Secondary Metabolites Tetrahydropalmatine and Rutaecarpine Alleviate Paclitaxel-Induced Neuropathic Pain via TRPV1 and TRPM8 Modulation.Metabolites · 2026Article
- Progress in Research on Alleviating the Symptoms Associated With Advanced Cancer Using Traditional Chinese Medicine.Pain research & management · 2026Review
- Soyeom-Jetong mixture attenuates NLRP3 inflammasome-mediated inflammation.Frontiers in pharmacology · 2026Article
- Narcotics through time: exploring historical origins, synthetic advances, and clinical progress.Future medicinal chemistry · 2025Review
- Antitumor Alkaloids in Tibetan Corydalis: Chemical Diversity and Pharmacological Insights.Medical science monitor : international medical journal of experimental and clinical research · 2025Review
- Recent Advances in Alkaloids fromMolecules (Basel, Switzerland) · 2024Review
- Interpreting the efficacy enhancement mechanism of Chinese medicine processing from a biopharmaceutic perspective.Chinese medicine · 2024Review
- Large variability in the alkaloid content ofFrontiers in pharmacology · 2024Article
- Identification ofMolecules (Basel, Switzerland) · 2023Article
- Application of digital-intelligence technology in the processing of Chinese materia medica.Frontiers in pharmacology · 2023Review
- Variation of Saponins inMolecules (Basel, Switzerland) · 2022Article
- Preclinical safety evaluation ofFrontiers in pharmacology · 2022Article
- Medication Rules in Herbal Medicine for Mild Cognitive Impairment: A Network Pharmacology and Data Mining Study.Evidence-based complementary and alternative medicine : eCAM · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Processed and polyherbal formulations (compatibility) are widely used in traditional Chinese medicine (TCM). However, processing and compatibility may alter the efficacy and safety of herbal medicines, and therefore, evaluating the herbal medicines changes after processing and compatibility is important for their safety. Since
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.